Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of AZD5069 in COPD
NCT01233232Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2010
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of azd5069 in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Nov 2010; status: completed.
02
Drugs
azd5069
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01233232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01233232.